Valirx (VAL) RNS Announcements

Add to Alert list
Date Time Source Announcement
07 Dec 2022 01:06 PM
RNS
Holding(s) in Company
06 Dec 2022 04:40 PM
RNS
Second Price Monitoring Extn
06 Dec 2022 04:35 PM
RNS
Price Monitoring Extension
06 Dec 2022 12:00 PM
RNS
Shareholder Communications and Investor Webinar
06 Dec 2022 07:00 AM
RNS
Quarterly Operational and Strategy Update
24 Oct 2022 07:00 AM
RNS
Subsidiary Launched and IP License Signed
18 Oct 2022 07:00 AM
RNS
Issue of Share Options
11 Oct 2022 07:00 AM
RNS
Director Appointment
30 Sep 2022 08:47 AM
RNS
Holding(s) in Company
22 Sep 2022 07:00 AM
RNS
Live Shareholder Q&A and industry events
08 Sep 2022 07:00 AM
RNS
Appointment of Interim Chief Scientific Officer
06 Sep 2022 07:15 AM
RNS
Proposed Appointment of Non-Executive Director
06 Sep 2022 07:00 AM
RNS
Issue of Share Options
31 Aug 2022 07:00 AM
RNS
Half-year Report
17 Aug 2022 07:00 AM
RNS
Shareholder Communications
14 Jul 2022 10:46 AM
RNS
Holding(s) in Company
13 Jul 2022 02:15 PM
RNS
Successful evaluation of breast cancer programme
07 Jul 2022 11:07 AM
RNS
Director/PDMR Shareholding
05 Jul 2022 11:45 AM
RNS
Holding(s) in Company
05 Jul 2022 07:00 AM
RNS
Broker Option Results
30 Jun 2022 03:00 PM
RNS
Result of AGM and Appointment of Joint Broker
30 Jun 2022 10:31 AM
RNS
Issue of Equity
30 Jun 2022 10:30 AM
RNS
Extends exclusivity period for TheoremRx
17 Jun 2022 10:01 AM
RNS
Update on VAL201 sub-license agreement
07 Jun 2022 04:33 PM
RNS
Annual Report, AGM Notice & Director Resignation
23 Mar 2022 07:00 AM
RNS
Update on proposed sub-license of VAL201
15 Mar 2022 07:00 AM
RNS
Operational and Strategy Update
14 Feb 2022 07:00 AM
RNS
Evaluation agreement with University of Barcelona
05 Jan 2022 04:41 PM
RNS
Second Price Monitoring Extn
05 Jan 2022 04:36 PM
RNS
Price Monitoring Extension
05 Jan 2022 02:06 PM
RNS
Second Price Monitoring Extn
05 Jan 2022 02:00 PM
RNS
Price Monitoring Extension
05 Jan 2022 11:00 AM
RNS
Price Monitoring Extension
05 Jan 2022 09:06 AM
RNS
Second Price Monitoring Extn
05 Jan 2022 09:00 AM
RNS
Price Monitoring Extension
05 Jan 2022 07:16 AM
RNS
Signs Service Agreement with TheoremRx
20 Dec 2021 07:00 AM
RNS
Amends License for VAL201 with CRT
16 Dec 2021 10:46 AM
RNS
Evaluation agreement with Hokkaido University
11 Nov 2021 07:00 AM
RNS
Live Shareholder Q&A and Investor presentations
08 Nov 2021 03:03 PM
RNS
Holding(s) in Company
02 Nov 2021 07:00 AM
RNS
Signs Letter of Intent to Sub-License VAL201
26 Oct 2021 02:00 PM
RNS
Price Monitoring Extension
26 Oct 2021 11:05 AM
RNS
Second Price Monitoring Extn
26 Oct 2021 11:00 AM
RNS
Price Monitoring Extension
26 Oct 2021 07:00 AM
RNS
Holding(s) in Company
20 Oct 2021 01:19 PM
RNS
Holding(s) in Company
19 Oct 2021 12:23 PM
RNS
Holding(s) in Company
18 Oct 2021 04:41 PM
RNS
Second Price Monitoring Extn
18 Oct 2021 04:36 PM
RNS
Price Monitoring Extension
18 Oct 2021 02:06 PM
RNS
Second Price Monitoring Extn

ValiRx PLC: A Biotech Innovator on the London Stock Exchange (LSE)

ValiRx PLC, known by its ticker symbol VAL, is a trailblazer in the biotechnology sector. Its performance on the London Stock Exchange (LSE) has been remarkable, with the ValiRx share price reflecting the company's consistent growth and success.

As a member of the LSE, ValiRx PLC aligns with the London Stock Exchange Group's (LSEG) mission of supporting innovative and growing businesses. The LSEG recognises ValiRx PLC as a significant player, contributing to the robust and diverse ecosystem of the LSE.

The ValiRx share price on the LSE not only underscores its financial stability but also its strategic vision in the biotechnology industry. ValiRx PLC's journey on the LSE is a testament to its robust business model and its ability to create value for its stakeholders.

In conclusion, ValiRx PLC's association with the LSE and LSEG symbolises its commitment to growth, innovation, and value creation. As ValiRx PLC continues to thrive on the LSE, it sets the bar high for the biotechnology industry, contributing to the dynamic and diverse ecosystem of the LSEG. With its focus on cancer therapeutics, ValiRx is a key player in the healthcare sector, making strides in medical research and development.

UK 100

Latest directors dealings